Neurogens aplindore effective in Phase II restless legs syndromw

Neurogen have announced Phase II clinical trial results with dopamine partial agonist aplindore in restless legs syndrome (RLS) and Parkinson’s disease. Aplindore demonstrated highly significant efficacy and was well tolerated.

Progenics completes enrollment in Phase II studies of CCR5 antagonist PRO-140

Progenics Pharmaceuticals have announced the completion of enrollment in two, phase 2 clinical studies of CCR5 antagonist PRO 140 in develompent for the treatment of human immunodeficiency virus (HIV)

Aeterna Zentaris reaches 2nd stage recruitment for AEZS-108 in Phase II ovarian cancer trial

Æterna Zentaris have reached the 2nd Stage of Patient Recruitment for its phase 2 Trial of LHRH-doxorubicin conjugate, AEZS-108 in Ovarian Cancer

Tranzyme release Phase IIb results with Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI)

Tranzyme Pharma have released positive Phase IIb results for its ghrelin agonist, TZP-101, in the management of postoperative ileus (POI).

Forest/Gedeon Richters Cariprazine effective in Acute Mania Associated with Bipolar I Disorder

Forest Laboratories  and Gedeon Richter have announced results from a phase II clinical trial of cariprazine (RGH-188) in patients with acute mania associated with bipolar I disorder. The data showed that patients with acute manic episodes treated with cariprazine experienced significant symptom improvement compared to placebo patients.

Oxford BioMedicas gene therapy ProSavin effective in parkinsons

Oxford BioMedica  have announced promising results from the Phase I/II trial of its gene therapy, ProSavin, for the treatment of Parkinson’s disease. It delivers three genes required to convert cells that normally do not produce dopamine into cells that do.

Targacept initiate Phase IIb of TC-5214 in Major Depressive Disorder

Targacept have initiated a Phase IIb trial of neuronal nicotinic receptor antagonist TC-5214 for the treatment of Major Depressive Disorder

Anesiva insitate Phase II trual of Adlea in Arthroscopic Shoulder Surgery

Anesiva have begun a Phase II clinical trial of Adlea, the company’s long-acting capsaicin product in for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

Nile Therapeutics begin Phase IIa with CD-NP in Heart Failure Patients

Nile Therapeutics have initiated a Phase IIa trial of its NPRb agonist CD-NP in acute setting heart failure patients.

Phase II data show 5HT1D agonist MAP0004 is effective in Migraine

Phase II data published in the July issue of Current Medical Research and Opinion show MAP Pharmaceutical’s 5HT1D agonist MAP0004, an orally inhaled and self-administered therapy, to demonstrate efficace in migraine.